Avraham Beigelman1, Leonard B Bacharier. 1. Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Washington University School of Medicine, and St Louis Children's Hospital, St Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to summarize the recent evidence on the management of preschool children with wheezing and asthma, and to propose a phenotype-based approach to the management of these children. RECENT FINDINGS: Recent studies have begun to identify populations of preschool children that are likely to benefit from inhaled corticosteroids (ICS) therapy and defined ICS regimens: daily ICS in preschool children with persistent asthma, and pre-emptive high-dose intermittent ICS among preschool children with intermittent disease reduce the risk of exacerbation. In addition, among preschool children with mild persistent asthma, the presence of aeroallergen sensitivity and/or blood eosinophil counts of 300/μL or greater are predictors of good response to daily ICS therapy. Other studies identified intermittent azithromycin as a therapy to prevent, and potentially to treat, acute exacerbations.The uncertainty of the role of oral corticosteroids (OCS) as a therapy for acute exacerbations continues, as a recent meta-analysis showed that OCS did not prevent hospitalizations or urgent visits, and did not reduce the need for additional courses of OCS. Whereas previous epidemiologic studies suggested acetaminophen may increase risk of exacerbations, a clinical trial clearly demonstrated acetaminophen use, compared to ibuprofen use,does not increase exacerbation risk among preschool children with mild-persistent asthma. SUMMARY: Recent studies have shown potential for phenotypic-driven therapies for the management of preschool children with asthma. Targeting airway bacteria has emerged as a promising therapeutic approach, but its effect on antibiotic resistance still needs to be investigated. Finally, more studies are required to evaluate if oral corticosteroids provide any benefits for acute episodic wheeze.
PURPOSE OF REVIEW: The purpose of this review is to summarize the recent evidence on the management of preschool children with wheezing and asthma, and to propose a phenotype-based approach to the management of these children. RECENT FINDINGS: Recent studies have begun to identify populations of preschool children that are likely to benefit from inhaled corticosteroids (ICS) therapy and defined ICS regimens: daily ICS in preschool children with persistent asthma, and pre-emptive high-dose intermittent ICS among preschool children with intermittent disease reduce the risk of exacerbation. In addition, among preschool children with mild persistent asthma, the presence of aeroallergen sensitivity and/or blood eosinophil counts of 300/μL or greater are predictors of good response to daily ICS therapy. Other studies identified intermittent azithromycin as a therapy to prevent, and potentially to treat, acute exacerbations.The uncertainty of the role of oral corticosteroids (OCS) as a therapy for acute exacerbations continues, as a recent meta-analysis showed that OCS did not prevent hospitalizations or urgent visits, and did not reduce the need for additional courses of OCS. Whereas previous epidemiologic studies suggested acetaminophen may increase risk of exacerbations, a clinical trial clearly demonstrated acetaminophen use, compared to ibuprofen use,does not increase exacerbation risk among preschool children with mild-persistent asthma. SUMMARY: Recent studies have shown potential for phenotypic-driven therapies for the management of preschool children with asthma. Targeting airway bacteria has emerged as a promising therapeutic approach, but its effect on antibiotic resistance still needs to be investigated. Finally, more studies are required to evaluate if oral corticosteroids provide any benefits for acute episodic wheeze.
Authors: Richard Beasley; Tadd Clayton; Julian Crane; Erika von Mutius; Christopher K W Lai; Stephen Montefort; Alistair Stewart Journal: Lancet Date: 2008-09-20 Impact factor: 79.321
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; David T Mauger; Susan J Boehmer; Stanley J Szefler; Leonard B Bacharier; Robert F Lemanske; Robert C Strunk; David B Allen; Gordon R Bloomberg; Gregory Heldt; Marzena Krawiec; Gary Larsen; Andrew H Liu; Vernon M Chinchilli; Christine A Sorkness; Lynn M Taussig; Fernando D Martinez Journal: N Engl J Med Date: 2006-05-11 Impact factor: 91.245
Authors: William J Sheehan; David T Mauger; Ian M Paul; James N Moy; Susan J Boehmer; Stanley J Szefler; Anne M Fitzpatrick; Daniel J Jackson; Leonard B Bacharier; Michael D Cabana; Ronina Covar; Fernando Holguin; Robert F Lemanske; Fernando D Martinez; Jacqueline A Pongracic; Avraham Beigelman; Sachin N Baxi; Mindy Benson; Kathryn Blake; James F Chmiel; Cori L Daines; Michael O Daines; Jonathan M Gaffin; Deborah A Gentile; W Adam Gower; Elliot Israel; Harsha V Kumar; Jason E Lang; Stephen C Lazarus; John J Lima; Ngoc Ly; Jyothi Marbin; Wayne J Morgan; Ross E Myers; J Tod Olin; Stephen P Peters; Hengameh H Raissy; Rachel G Robison; Kristie Ross; Christine A Sorkness; Shannon M Thyne; Michael E Wechsler; Wanda Phipatanakul Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Leonard B Bacharier; Brenda R Phillips; Gordon R Bloomberg; Robert S Zeiger; Ian M Paul; Marzena Krawiec; Theresa Guilbert; Vernon M Chinchilli; Robert C Strunk Journal: J Allergy Clin Immunol Date: 2007-03 Impact factor: 10.793
Authors: Martin Depner; Oliver Fuchs; Jon Genuneit; Anne M Karvonen; Anne Hyvärinen; Vincent Kaulek; Caroline Roduit; Juliane Weber; Bianca Schaub; Roger Lauener; Michael Kabesch; Petra Ina Pfefferle; Urs Frey; Juha Pekkanen; Jean-Charles Dalphin; Josef Riedler; Charlotte Braun-Fahrländer; Erika von Mutius; Markus J Ege Journal: Am J Respir Crit Care Med Date: 2014-01-15 Impact factor: 21.405
Authors: Leonard B Bacharier; Theresa W Guilbert; Robert S Zeiger; Robert C Strunk; Wayne J Morgan; Robert F Lemanske; Mark Moss; Stanley J Szefler; Marzena Krawiec; Susan Boehmer; David Mauger; Lynn M Taussig; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2009-02-23 Impact factor: 10.793
Authors: Avraham Beigelman; Tonya S King; David Mauger; Robert S Zeiger; Robert C Strunk; H William Kelly; Fernando D Martinez; Robert F Lemanske; Katherine Rivera-Spoljaric; Daniel J Jackson; Theresa Guilbert; Ronina Covar; Leonard B Bacharier Journal: J Allergy Clin Immunol Date: 2013-03-14 Impact factor: 10.793
Authors: Chinedu Nwokoro; Hitesh Pandya; Stephen Turner; Sandra Eldridge; Christopher J Griffiths; Tom Vulliamy; David Price; Marek Sanak; John W Holloway; Rossa Brugha; Lee Koh; Iain Dickson; Clare Rutterford; Jonathan Grigg Journal: Lancet Respir Med Date: 2014-09-08 Impact factor: 30.700
Authors: Helena Donath; Sven Kluge; Georgia Sideri; Jordis Trischler; Silivija P Jerkic; Johannes Schulze; Stefan Zielen; Katharina Blumchen Journal: Front Pediatr Date: 2020-11-20 Impact factor: 3.418
Authors: Stefan Zielen; Gianna Reichert; Helena Donath; Jordis Trischler; Johannes Schulze; Olaf Eickmeier; Martin Eckrich; Katharina Blumchen Journal: J Asthma Allergy Date: 2021-01-14
Authors: Karamarie Fecho; Stanley C Ahalt; Stephen Appold; Saravanan Arunachalam; Emily Pfaff; Lisa Stillwell; Alejandro Valencia; Hao Xu; David B Peden Journal: JMIR Form Res Date: 2022-04-01
Authors: Leonard B Bacharier; Avraham Beigelman; Agustin Calatroni; Daniel J Jackson; Peter J Gergen; George T O'Connor; Meyer Kattan; Robert A Wood; Megan T Sandel; Susan V Lynch; Kei E Fujimura; Douglas W Fadrosh; Clark A Santee; Homer Boushey; Cynthia M Visness; James E Gern Journal: Am J Respir Crit Care Med Date: 2019-01-01 Impact factor: 30.528